Hariharan Saminathan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hariharan Saminathan has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Aishwarya M. Johnson
Department of Veterinary Medicine, College of Food and Agriculture, United Arab Emirates University, Al Ain, UAE
1 shared publication- Aishwarya Mary Johnson
Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, The United Arab Emirates University, Al Ain, UAE
1 shared publication - Richard Gordon
UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, QLD 4029, Australia
1 shared publication - Robert Barigye
Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, United Arab Emirates University, Al Ain, United Arab Emirates
1 shared publication Zhen-Yi Andy Ou
Translational Neuroscience Laboratory, UQ Centre for Clinical Research, The University of Queensland, Australia; School of Biomedical Sciences, University of Queensland, Australia
1 shared publication
Latest Publications
- 1 January 2022
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 142, 106113
Environmental neurotoxicants and inflammasome activation in Parkinson’s disease – A focus on the gut-brain axis
- 1 January 2022
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 142, 106113
Environmental neurotoxicants and inflammasome activation in Parkinson’s disease – A focus on the gut-brain axis
- 11 May 2021
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (9) , 2824-2840
Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel coronavirus disease 2019 (COVID-19) pandemic that lacks globally accessible effective antivirals or extensively available vaccines. Numerous clinical trials are exploring the applicability of repurposed monoclonal antibodies (mAbs) targeting cytokines that cause adverse COVID-19-related pathologies, and novel mAbs directly targeting SARS-CoV-2. However, comorbidities and the incidence of cytokine storm (CS)-associated pathological complexities in some COVID-19 patients may limit the clinical use of these drugs. Additionally, CS-targeting mAbs have the potential to cause adverse events that restrict their applicability in patients with comorbidities. Novel mAbs targeting SARS-CoV-2 require pharmacological and toxicological characterization before a marketable product becomes available. The affordability of novel mAbs across the global economic spectrum may seriously limit their accessibility. This review presents a perspective on antibody-based research efforts and their limitations for COVID-19.
- 11 May 2021
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (9) , 2824-2840
Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel coronavirus disease 2019 (COVID-19) pandemic that lacks globally accessible effective antivirals or extensively available vaccines. Numerous clinical trials are exploring the applicability of repurposed monoclonal antibodies (mAbs) targeting cytokines that cause adverse COVID-19-related pathologies, and novel mAbs directly targeting SARS-CoV-2. However, comorbidities and the incidence of cytokine storm (CS)-associated pathological complexities in some COVID-19 patients may limit the clinical use of these drugs. Additionally, CS-targeting mAbs have the potential to cause adverse events that restrict their applicability in patients with comorbidities. Novel mAbs targeting SARS-CoV-2 require pharmacological and toxicological characterization before a marketable product becomes available. The affordability of novel mAbs across the global economic spectrum may seriously limit their accessibility. This review presents a perspective on antibody-based research efforts and their limitations for COVID-19.